Recent Development News: Q2 – 2017

ROOT9B HOLDINGS ADDED TO RUSSELL MICROCAP® INDEX

- root9B Holdings Inc. (NASDAQ: RTNB), a leading provider of advanced cybersecurity products, services and training, has been added to the Russell Microcap® Index, effective today. Russell Investments reconstituted its family of U.S. indexes after the close of the U.S. … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

root9B Remains #1 on Cybersecurity 500 For 6th Consecutive Quarter

COLORADO SPRINGS, Colo., June 23, 2017 — In response to remaining #1 on the Cybersecurity 500 for six consecutive quarters, root9B’s Chief Executive Officer Eric Hipkins issued the following statement: “root9B’s continued #1 presence on the Cybersecurity 500 is a … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

root9B Releases Technical Analysis on Active Malware Campaign After Briefing Law Enforcement

root9B, a root9B Holdings Inc. (NASDAQ: RTNB) company, and leading provider of advanced cybersecurity products, services, and training, has released an in-depth technical analysis report on a newly identified active campaign targeting point-of-sale systems. The report provides technical details of … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

Edge Therapeutics to Participate in the JMP Securities Life Science Conference

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life threatening conditions, today announced that President and Chief Executive Officer Brian A. Leuthner will participate in the panel discussion “Hospital Drug Launches … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

Edge Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life threatening conditions, today announced that it received a product-specific pediatric waiver from the European Medicines Agency (EMA) for EG-1962, Edge’s lead product … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off